|
EP1519714B1
(de)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Verfahren und vorrichtung zur herstellung von liposomen
|
|
US7718189B2
(en)
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
|
AU2004257373B2
(en)
*
|
2003-07-16 |
2011-03-24 |
Arbutus Biopharma Corporation |
Lipid encapsulated interfering RNA
|
|
US9198645B2
(en)
*
|
2003-11-26 |
2015-12-01 |
The United States of America, as represented by the Secretary of Commerce of The National Institute of Standards and Technology |
Controlled vesicle self-assembly in continuous two phase flow microfluidic channels
|
|
US8658203B2
(en)
|
2004-05-03 |
2014-02-25 |
Merrimack Pharmaceuticals, Inc. |
Liposomes useful for drug delivery to the brain
|
|
KR101462825B1
(ko)
|
2004-05-03 |
2014-11-21 |
헤르메스 바이오사이언스, 인코포레이티드 |
약물 전달에 유용한 리포좀
|
|
US8715591B2
(en)
*
|
2004-07-21 |
2014-05-06 |
The United States of America, as represented by the Secretary of Commerce, The National Institute of Standards and Technology |
Microfluidic apparatus to control liposome formation
|
|
ATE454884T1
(de)
*
|
2004-10-18 |
2010-01-15 |
Polymun Scient Immunbio Forsch |
Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung
|
|
US9393315B2
(en)
|
2011-06-08 |
2016-07-19 |
Nitto Denko Corporation |
Compounds for targeting drug delivery and enhancing siRNA activity
|
|
JP2006248978A
(ja)
*
|
2005-03-10 |
2006-09-21 |
Mebiopharm Co Ltd |
新規なリポソーム製剤
|
|
US8895717B2
(en)
|
2005-04-15 |
2014-11-25 |
The Board Of Regents Of The University Of Texas System |
Delivery of siRNA by neutral lipid compositions
|
|
JP5639338B2
(ja)
*
|
2005-07-27 |
2014-12-10 |
プロチバ バイオセラピューティクス インコーポレイティッド |
リポソームの製造システムおよび製造方法
|
|
EP1934348B1
(de)
*
|
2005-10-11 |
2018-05-02 |
Ben-Gurion University Of The Negev Research And Development Authority |
Zusammensetzung zum silencing der expression von vdac1 und verwendungen davon
|
|
EP1948674A4
(de)
|
2005-11-02 |
2009-02-04 |
Protiva Biotherapeutics Inc |
Modifizierte sirna-moleküle und anwendungen davon
|
|
ES2798263T3
(es)
|
2005-12-08 |
2020-12-10 |
Insmed Inc |
Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
|
|
WO2007117550A2
(en)
*
|
2006-04-06 |
2007-10-18 |
Transave, Inc. |
Methods for coacervation induced liposomal encapsulation and formulations thereof
|
|
KR101128639B1
(ko)
*
|
2006-11-17 |
2012-03-26 |
현대중공업 주식회사 |
휠식 건설기계의 핸들 및 조이스틱 조향을 위한유압제어장치
|
|
JP5415283B2
(ja)
|
2007-02-07 |
2014-02-12 |
グラダリス インク. |
シアル酸産生を調節し、遺伝性封入体ミオパチーを治療する方法及び組成物
|
|
WO2008109432A2
(en)
|
2007-03-02 |
2008-09-12 |
The Board Of Regents Of The University Of Texas System |
Therapeutic targeting of interleukins using sirna in neutral liposomes
|
|
WO2008137717A1
(en)
|
2007-05-04 |
2008-11-13 |
Transave, Inc. |
Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
|
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
|
US9333214B2
(en)
|
2007-05-07 |
2016-05-10 |
Insmed Incorporated |
Method for treating pulmonary disorders with liposomal amikacin formulations
|
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
|
EP2153820A4
(de)
|
2007-05-14 |
2013-12-25 |
Konica Minolta Holdings Inc |
Liposom und verfahren zur herstellung des liposoms
|
|
AU2008308679B2
(en)
*
|
2007-10-02 |
2015-01-29 |
Marina Biotech, Inc. |
Lipopeptides for delivery of nucleic acids
|
|
US9006191B2
(en)
|
2007-12-27 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering RNA
|
|
EP2279254B1
(de)
|
2008-04-15 |
2017-07-05 |
Protiva Biotherapeutics Inc. |
Neue lipidformulierungen zur nukleinsäurezuführung
|
|
WO2009129319A2
(en)
|
2008-04-15 |
2009-10-22 |
Protiva Biotherapeutics, Inc. |
Silencing of csn5 gene expression using interfering rna
|
|
WO2009149418A2
(en)
*
|
2008-06-06 |
2009-12-10 |
Asuragen, Inc. |
Novel compositions for the in vivo delivery of rnai agents
|
|
AU2009303345B2
(en)
|
2008-10-09 |
2015-08-20 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
CN104382853A
(zh)
*
|
2008-10-16 |
2015-03-04 |
玛瑞纳生物技术有限公司 |
基因沉默治疗剂的脂质体有效递送方法和组合物
|
|
AU2009320006A1
(en)
|
2008-10-30 |
2010-06-03 |
Peixuan Guo |
Membrane-integrated viral DNA-packaging motor protein connector biosensor for DNA sequencing and other uses
|
|
EP3699172A3
(de)
|
2008-11-10 |
2020-11-18 |
Arbutus Biopharma Corporation |
Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
WO2012098692A1
(ja)
*
|
2011-01-19 |
2012-07-26 |
協和発酵キリン株式会社 |
標的遺伝子の発現を抑制する組成物
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
WO2011038160A2
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
RU2573409C2
(ru)
|
2009-11-04 |
2016-01-20 |
Дзе Юниверсити Оф Бритиш Коламбиа |
Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы
|
|
JP5647143B2
(ja)
*
|
2009-11-30 |
2014-12-24 |
株式会社 資生堂 |
ポリマーソーム及び製造方法
|
|
SI2506857T1
(en)
|
2009-12-01 |
2018-08-31 |
Translate Bio, Inc. |
Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
|
|
MX339050B
(es)
|
2009-12-18 |
2016-05-09 |
Novartis Ag |
Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
|
|
MX2012009318A
(es)
|
2010-02-10 |
2012-09-07 |
Novartis Ag |
Metodos y compuestos para el crecimiento muscular.
|
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
|
EP3391877A1
(de)
|
2010-04-08 |
2018-10-24 |
The Trustees of Princeton University |
Herstellung von lipidnanopartikeln
|
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
|
CA3098080A1
(en)
|
2010-04-23 |
2011-10-27 |
Arrowhead Research Corporation |
Organic compositions to treat beta-enac-related diseases
|
|
WO2011139842A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
|
|
US10077232B2
(en)
|
2010-05-12 |
2018-09-18 |
Arbutus Biopharma Corporation |
Cyclic cationic lipids and methods of use
|
|
US20130123338A1
(en)
|
2010-05-12 |
2013-05-16 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
EP4481047A3
(de)
|
2010-06-03 |
2025-04-16 |
Alnylam Pharmaceuticals, Inc. |
Biologisch abbaubare lipide zur freisetzung von wirkstoffen
|
|
US9387152B2
(en)
|
2010-06-28 |
2016-07-12 |
The General Hospital Corporation |
Blood substitutes and uses thereof
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
CN103153284B
(zh)
|
2010-07-06 |
2015-11-25 |
诺华股份有限公司 |
含有其pKa值有利于RNA递送的脂质的脂质体
|
|
US10487332B2
(en)
|
2010-07-06 |
2019-11-26 |
Glaxosmithkline Biologicals Sa |
Immunisation of large mammals with low doses of RNA
|
|
FI4005592T3
(fi)
|
2010-07-06 |
2023-01-13 |
|
Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
PT3243526T
(pt)
|
2010-07-06 |
2020-03-04 |
Glaxosmithkline Biologicals Sa |
Distribuição de arn para despoletar múltiplas vias imunitárias
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
JP5911870B2
(ja)
|
2010-08-31 |
2016-04-27 |
ノバルティス アーゲー |
免疫原をコードするrnaの送達のためのpeg化リポソーム
|
|
EP2857499A1
(de)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Manipulierte Nukleinsäuren und Verfahren zur Verwendung davon
|
|
KR102266691B1
(ko)
*
|
2010-10-11 |
2021-06-23 |
노파르티스 아게 |
항원 전달 플랫폼
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
US20120244209A1
(en)
|
2011-03-02 |
2012-09-27 |
Roth Jack A |
Tusc2 therapies
|
|
RU2571077C2
(ru)
*
|
2011-03-25 |
2015-12-20 |
Терумо Кабусики Кайся |
Липосомальная композиция длительного действия с контролируемым высвобождением и способ ее получения
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
|
KR20220025112A
(ko)
|
2011-06-08 |
2022-03-03 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Mrna 전달을 위한 지질 나노입자 조성물 및 방법
|
|
US9011903B2
(en)
|
2011-06-08 |
2015-04-21 |
Nitto Denko Corporation |
Cationic lipids for therapeutic agent delivery formulations
|
|
JP2014522842A
(ja)
|
2011-07-06 |
2014-09-08 |
ノバルティス アーゲー |
免疫原性組み合わせ組成物およびその使用
|
|
PT2750707T
(pt)
|
2011-08-31 |
2019-01-23 |
Glaxosmithkline Biologicals Sa |
Lipossomas peguilados para distribuição de arn que codifica imunogénio
|
|
US20160032284A1
(en)
|
2011-09-02 |
2016-02-04 |
Arrowhead Research Corportation |
Organic compositions to treat hsf1-related diseases
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
US20140328759A1
(en)
|
2011-10-25 |
2014-11-06 |
The University Of British Columbia |
Limit size lipid nanoparticles and related methods
|
|
CA2853689C
(en)
|
2011-11-04 |
2020-06-30 |
Nitto Denko Corporation |
Method of producing lipid nanoparticles for drug delivery
|
|
DE21212055T1
(de)
|
2011-12-07 |
2022-08-04 |
Alnylam Pharmaceuticals, Inc. |
Biologisch abbaubare lipide zur freisetzung von wirkstoffen
|
|
WO2013086322A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
BR112014016870A2
(pt)
|
2012-01-09 |
2017-06-27 |
Huesken Dieter |
composições orgânicas para tratar doenças relacionadas com beta-catenina
|
|
US9352042B2
(en)
|
2012-02-24 |
2016-05-31 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
BR112014024131A2
(pt)
|
2012-03-29 |
2017-07-25 |
Shire Human Genetic Therapies |
lipídios catiônicos ionizáveis
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
EP2841572B1
(de)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetische korrektur mutierter gene
|
|
CN104583406A
(zh)
|
2012-05-02 |
2015-04-29 |
诺华股份有限公司 |
治疗kras相关疾病的有机组合物
|
|
CA2872519C
(en)
|
2012-05-04 |
2017-09-05 |
The Johns Hopkins University |
Lipid-based drug carriers for rapid penetration through mucus linings
|
|
KR101493961B1
(ko)
*
|
2012-05-16 |
2015-02-17 |
한국생명공학연구원 |
압출공정 없이 핵산 함유 나노 리포솜을 제조하는 방법
|
|
PL2852391T3
(pl)
|
2012-05-21 |
2022-04-11 |
Insmed Incorporated |
Układy do leczenia infekcji płuc
|
|
EA201492055A1
(ru)
|
2012-06-08 |
2015-11-30 |
Шир Хьюман Дженетик Терапис, Инк. |
ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
|
|
EP3536787A1
(de)
|
2012-06-08 |
2019-09-11 |
Translate Bio, Inc. |
Nukleaseresistente polynukleotide und verwendungen davon
|
|
WO2014015027A1
(en)
|
2012-07-18 |
2014-01-23 |
Onyx Therapeutics, Inc. |
Liposomal compositions of epoxyketone-based proteasome inhibitors
|
|
CN110464709A
(zh)
|
2012-08-10 |
2019-11-19 |
德克萨斯州大学系统董事会 |
用于治疗中风的神经保护性脂质体组合物和方法
|
|
WO2014046191A1
(ja)
|
2012-09-21 |
2014-03-27 |
テルモ株式会社 |
局所麻酔薬持続徐放性リポソーム製剤
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
CA2891487A1
(en)
|
2012-11-29 |
2014-06-05 |
Insmed Incorporated |
Stabilized vancomycin formulations
|
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
|
HK1214301A1
(zh)
|
2013-02-28 |
2016-07-22 |
箭头研究公司 |
治療epas1相關疾病的有機組合物
|
|
EP3932947A1
(de)
|
2013-03-14 |
2022-01-05 |
Translate Bio MA, Inc. |
Verfahren und zusammensetzungen zur abgabe von mrna-codierten antikörpern
|
|
EA201591229A1
(ru)
|
2013-03-14 |
2016-01-29 |
Шир Хьюман Дженетик Терапис, Инк. |
Способы очистки матричной рнк
|
|
CA3120574A1
(en)
|
2013-03-14 |
2014-09-25 |
Dicerna Pharmaceuticals, Inc. |
Process for formulating an anionic agent
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
KR102311614B1
(ko)
|
2013-03-14 |
2021-10-08 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Cftr mrna 조성물 및 관련 방법 및 사용
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
ES2967701T3
(es)
|
2013-03-15 |
2024-05-03 |
Translate Bio Inc |
Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
|
|
US9693958B2
(en)
|
2013-03-15 |
2017-07-04 |
Cureport, Inc. |
Methods and devices for preparation of lipid nanoparticles
|
|
CN105143456A
(zh)
|
2013-03-15 |
2015-12-09 |
不列颠哥伦比亚大学 |
用于转染的脂质纳米粒子和相关方法
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
SG11201510327TA
(en)
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
KR20250012194A
(ko)
|
2013-06-17 |
2025-01-23 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
|
JP6738728B2
(ja)
|
2013-06-17 |
2020-08-19 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
肝臓ターゲティングおよび治療のためのCRISPR−Cas系、ベクターおよび組成物の送達および使用
|
|
WO2015011633A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
|
WO2015048020A2
(en)
*
|
2013-09-24 |
2015-04-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for the manufacture of lipid nanoparticles
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
WO2015051135A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Organic compositions to treat hepcidin-related diseases
|
|
ES3032935T3
(en)
|
2013-10-22 |
2025-07-29 |
Translate Bio Inc |
Lipid formulations for delivery of messenger rna
|
|
EP3574923A1
(de)
|
2013-10-22 |
2019-12-04 |
Translate Bio, Inc. |
Mrna-therapie für phenylketonurie
|
|
AU2014340149B2
(en)
|
2013-10-22 |
2020-12-24 |
Shire Human Genetic Therapies, Inc. |
CNS delivery of mRNA and uses thereof
|
|
ES2707966T3
(es)
|
2013-10-22 |
2019-04-08 |
Translate Bio Inc |
Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
|
|
US10542918B2
(en)
|
2013-10-23 |
2020-01-28 |
Verily Life Sciences Llc |
Modulation of a response signal to distinguish between analyte and background signals
|
|
US9504405B2
(en)
|
2013-10-23 |
2016-11-29 |
Verily Life Sciences Llc |
Spatial modulation of magnetic particles in vasculature by external magnetic field
|
|
WO2015089419A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
CN111206032B
(zh)
|
2013-12-12 |
2024-07-19 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
|
|
KR20160097338A
(ko)
|
2013-12-12 |
2016-08-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
뉴클레오티드 반복 장애에서의 crispr-cas 시스템의 조성물 및 방법 및 용도
|
|
WO2015089473A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
CN105899658B
(zh)
|
2013-12-12 |
2020-02-18 |
布罗德研究所有限公司 |
针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
AR094658A1
(es)
*
|
2014-01-14 |
2015-08-19 |
Fast Rehydration Llc |
Formulación de sales de rehidratación liposomal
|
|
US10751283B2
(en)
|
2014-01-14 |
2020-08-25 |
Capability Building, Inc. |
Liposomal rehydration salt formulation and associated methods of use
|
|
EA037503B1
(ru)
|
2014-01-21 |
2021-04-05 |
Анджариум Байосайенсиз Аг |
Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства
|
|
HRP20220070T1
(hr)
|
2014-04-23 |
2022-04-01 |
Modernatx, Inc. |
Cjepiva nukleinske kiseline
|
|
EP4729528A3
(de)
|
2014-04-25 |
2026-06-24 |
Translate Bio, Inc. |
Verfahren zur reinigung von messenger-rna
|
|
MX384843B
(es)
|
2014-05-15 |
2025-03-14 |
Insmed Inc |
Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
|
|
WO2015184256A2
(en)
|
2014-05-30 |
2015-12-03 |
Shire Human Genetic Therapies, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
|
CA2952121A1
(en)
|
2014-06-13 |
2015-12-17 |
Childrens' Medical Center Corporation |
Products and methods to isolate mitochondria
|
|
KR102559979B1
(ko)
|
2014-06-24 |
2023-07-25 |
샤이어 휴먼 지네틱 테라피즈 인크. |
핵산의 전달용 입체화학적으로 풍부한 조성물
|
|
CA2953341C
(en)
|
2014-06-25 |
2023-01-24 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2016004318A1
(en)
*
|
2014-07-02 |
2016-01-07 |
Shire Human Genetic Therapies, Inc. |
Encapsulation of messenger rna
|
|
EP3736334A1
(de)
|
2014-07-16 |
2020-11-11 |
Arrowhead Pharmaceuticals, Inc. |
Irna-zusammensetzungen zur behandlung von apoc3-bedingten erkrankungen
|
|
EP3180426B1
(de)
|
2014-08-17 |
2019-12-25 |
The Broad Institute, Inc. |
Gemonbearbeitung mit cas9-nickasen
|
|
US9765333B2
(en)
|
2014-08-21 |
2017-09-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing marburg virus gene expression
|
|
WO2016038550A1
(en)
|
2014-09-11 |
2016-03-17 |
Novartis Ag |
Inhibition of prmt5 to treat mtap-deficiency-related diseases
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
US10415037B2
(en)
|
2014-10-02 |
2019-09-17 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis B virus gene expression
|
|
EP3227446A1
(de)
|
2014-12-01 |
2017-10-11 |
Novartis AG |
Zusammensetzungen und verfahren zur diagnose und behandlung von prostatakrebs
|
|
AU2015357562B2
(en)
|
2014-12-05 |
2021-10-21 |
Translate Bio, Inc. |
Messenger RNA therapy for treatment of articular disease
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
EP3985115A1
(de)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Geschützte guide-rnas (pgrnas)
|
|
EP3230452B1
(de)
|
2014-12-12 |
2025-06-11 |
The Broad Institute, Inc. |
Deaktivierte guides für crispr-transkriptionsfaktoren
|
|
EP3234192B1
(de)
|
2014-12-19 |
2021-07-14 |
The Broad Institute, Inc. |
Unbeeinflusste identifizierung von doppelstrangbrüchen und genomischer umordnung durch genomweite einsatzerfassungssequenzierung
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
WO2016106244A1
(en)
|
2014-12-24 |
2016-06-30 |
The Broad Institute Inc. |
Crispr having or associated with destabilization domains
|
|
US9861710B1
(en)
|
2015-01-16 |
2018-01-09 |
Verily Life Sciences Llc |
Composite particles, methods, and in vivo diagnostic system
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
EP3271057B1
(de)
|
2015-03-19 |
2019-09-04 |
The University of Connecticut |
Systeme und verfahren zur kontinuierlichen herstellung von liposomen arzneimittelformulierungen
|
|
EP3270894B1
(de)
|
2015-03-19 |
2021-02-24 |
Translate Bio, Inc. |
Mrna-therapie für pompe-krankheit
|
|
WO2016153012A1
(ja)
|
2015-03-24 |
2016-09-29 |
協和発酵キリン株式会社 |
核酸含有脂質ナノ粒子
|
|
KR20180016347A
(ko)
*
|
2015-04-13 |
2018-02-14 |
파운테인 테크놀로지스 인터내셔널, 엘엘씨 |
초-소형 지질 구조체의 생산을 위한 단일-단계 방법
|
|
EP4353257A3
(de)
|
2015-04-13 |
2024-08-07 |
CureVac Manufacturing GmbH |
Verfahren zur herstellung von rna-zusammensetzungen
|
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
|
EP3302525A2
(de)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
|
|
CA3012631A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
WO2016205745A2
(en)
*
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
EP3929287A3
(de)
|
2015-06-18 |
2022-04-13 |
The Broad Institute, Inc. |
Crispr-enzym-mutationen zur reduzierung von off-target-effekten
|
|
HUE067372T2
(hu)
|
2015-06-29 |
2024-10-28 |
Acuitas Therapeutics Inc |
Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
|
|
CN108350455A
(zh)
|
2015-07-29 |
2018-07-31 |
阿布特斯生物制药公司 |
用于使b型肝炎病毒基因表达沉默的组合物和方法
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
AU2016308339A1
(en)
|
2015-08-18 |
2018-04-12 |
Baylor College Of Medicine |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
MX2018002090A
(es)
|
2015-08-24 |
2018-09-12 |
Halo Bio Rnai Therapeutics Inc |
Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
|
|
HRP20220156T1
(hr)
|
2015-09-17 |
2022-04-15 |
Modernatx, Inc. |
Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
ES2862412T3
(es)
|
2015-10-14 |
2021-10-07 |
Translate Bio Inc |
Modificación de enzimas relacionados con el ARN para producción mejorada
|
|
ES3036518T3
(en)
|
2015-10-16 |
2025-09-19 |
Ipsen Biopharm Ltd |
Stabilizing camptothecin pharmaceutical compositions
|
|
CN116814590A
(zh)
|
2015-10-22 |
2023-09-29 |
布罗德研究所有限公司 |
Vi-b型crispr酶和系统
|
|
US11492670B2
(en)
|
2015-10-27 |
2022-11-08 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2018081480A1
(en)
|
2016-10-26 |
2018-05-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
CN108368028B
(zh)
|
2015-10-28 |
2021-09-03 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
US12214054B2
(en)
|
2015-11-30 |
2025-02-04 |
Duke University |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
|
US20170151287A1
(en)
|
2015-11-30 |
2017-06-01 |
Flagship Ventures Management, Inc. |
Methods and compositions of chondrisomes
|
|
DK3386484T3
(da)
|
2015-12-10 |
2022-07-04 |
Modernatx Inc |
Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
|
|
EP3389650B1
(de)
|
2015-12-18 |
2022-01-12 |
The Board of Regents of The University of Texas System |
Therapeutika für das frühgeburtenmanagement
|
|
WO2017106657A1
(en)
|
2015-12-18 |
2017-06-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
RS63051B1
(sr)
|
2015-12-22 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularnu isporuku agenasa
|
|
US12678515B2
(en)
|
2015-12-30 |
2026-07-14 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
ES3057779T3
(en)
|
2016-01-15 |
2026-03-04 |
Childrens Medical Ct Corp |
Therapeutic use of mitochondria and combined mitochondrial agents
|
|
AU2017248189B2
(en)
|
2016-04-08 |
2021-04-29 |
Translate Bio, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
EP3443081A4
(de)
|
2016-04-13 |
2019-10-30 |
Duke University |
Crispr/cas9-basierte repressoren zur in-vivo-ausschaltung von gen-targets und verfahren zur verwendung
|
|
EP3445853A1
(de)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1-komplexe mit reduzierter indelaktivität
|
|
CA3026110A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
KR20260004568A
(ko)
|
2016-04-19 |
2026-01-08 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
|
AU2017283479B2
(en)
|
2016-06-13 |
2023-08-17 |
Translate Bio, Inc. |
Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
|
|
AU2017283713B2
(en)
|
2016-06-17 |
2021-04-08 |
Massachusetts Institute Of Technology |
Type VI CRISPR orthologs and systems
|
|
WO2018005873A1
(en)
|
2016-06-29 |
2018-01-04 |
The Broad Institute Inc. |
Crispr-cas systems having destabilization domain
|
|
US11191849B2
(en)
|
2016-06-30 |
2021-12-07 |
Arbutus Biopharma Corporation |
Compositions and methods for delivering messenger RNA
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Cpf1に基づくゲノム編集の治療適用
|
|
CN106074402A
(zh)
*
|
2016-07-28 |
2016-11-09 |
浙江美保龙生物技术有限公司 |
一种猪细小病毒脂质体稀释液冻干制品及其制备方法
|
|
CN106074404A
(zh)
*
|
2016-08-17 |
2016-11-09 |
浙江美保龙生物技术有限公司 |
一种猪繁殖与呼吸综合征病毒脂质体稀释液冻干制品及其制备方法
|
|
US11352647B2
(en)
|
2016-08-17 |
2022-06-07 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2018035387A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
WO2018039131A1
(en)
|
2016-08-22 |
2018-03-01 |
Protiva Biotherapeutics, Inc. |
Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
WO2018047148A1
(en)
|
2016-09-12 |
2018-03-15 |
Novartis Ag |
Compounds for the inhibition of mirna
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2018071668A1
(en)
|
2016-10-12 |
2018-04-19 |
Board Of Regents, The University Of Texas System |
Methods and compositions for tusc2 immunotherapy
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
EP3538067A1
(de)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilisierte formulierungen von lipidnanopartikeln
|
|
CN109996809A
(zh)
|
2016-11-14 |
2019-07-09 |
诺华股份有限公司 |
与促融合蛋白minion相关的组合物、方法和治疗用途
|
|
RU2019121801A
(ru)
|
2016-12-14 |
2021-01-15 |
Лигандал, Инк. |
Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка
|
|
AU2017379901B2
(en)
|
2016-12-21 |
2024-02-15 |
Arbutus Biopharma Corporation |
Methods for ameliorating infusion reactions
|
|
MX2019010155A
(es)
|
2017-02-27 |
2020-12-10 |
Translate Bio Inc |
Arnm de cftr optimizado por codón novedoso.
|
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
|
CN110959039B
(zh)
|
2017-03-15 |
2025-03-14 |
博德研究所 |
新型cas13b直向同源物crispr酶和系统
|
|
WO2018170322A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
|
US11338045B2
(en)
|
2017-03-17 |
2022-05-24 |
Newcastle University |
Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
|
|
CA3059426A1
(en)
|
2017-04-11 |
2018-10-18 |
Arbutus Biopharma Corporation |
Targeted compositions
|
|
AU2018251801B2
(en)
|
2017-04-12 |
2024-11-07 |
Massachusetts Institute Of Technology |
Novel type VI CRISPR orthologs and systems
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018191750A2
(en)
|
2017-04-14 |
2018-10-18 |
The Broad Institute Inc. |
Novel delivery of large payloads
|
|
US11820728B2
(en)
|
2017-04-28 |
2023-11-21 |
Acuitas Therapeutics, Inc. |
Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
|
US11576872B2
(en)
|
2017-05-08 |
2023-02-14 |
Flagship Pioneering Innovations V, Inc. |
Compositions for facilitating membrane fusion and uses thereof
|
|
IL270631B2
(en)
|
2017-05-16 |
2024-03-01 |
Translate Bio Inc |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
|
EP3625342B1
(de)
|
2017-05-18 |
2022-08-24 |
The Broad Institute, Inc. |
Systeme, verfahren und zusammensetzungen zur gezielten nukleinsäureeditierung
|
|
CA3066750A1
(en)
|
2017-06-13 |
2018-12-20 |
Flagship Pioneering Innovations V, Inc. |
Compositions comprising curons and uses thereof
|
|
EP3638678B1
(de)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Verbindungen und zusammensetzungen zur intrazellulären verabreichung von wirkstoffen
|
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
EP4085919A3
(de)
|
2017-07-21 |
2023-02-08 |
Novartis AG |
Zusammensetzungen und verfahren zur behandlung von krebs
|
|
CA3071968A1
(en)
|
2017-08-04 |
2019-02-07 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticle
|
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
JP7461872B2
(ja)
|
2017-08-17 |
2024-04-04 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
IT201700099627A1
(it)
*
|
2017-09-06 |
2019-03-06 |
Anna Angela Barba |
Produzione di vettori nano-liposomiali incapsulanti ferro altamente biodisponibile con tecnica in continuo.
|
|
SG11201912178VA
(en)
|
2017-09-11 |
2020-01-30 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
|
|
KR102338449B1
(ko)
|
2017-09-21 |
2021-12-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
|
|
WO2019071054A1
(en)
|
2017-10-04 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
|
|
US12227742B2
(en)
|
2017-10-23 |
2025-02-18 |
The Broad Institute, Inc. |
Nucleic acid modifiers
|
|
US11547614B2
(en)
|
2017-10-31 |
2023-01-10 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
CN111565833B
(zh)
*
|
2017-11-01 |
2023-04-07 |
国立大学法人大阪大学 |
用于制造具有期望的粒径的脂质颗粒的方法及装置的开发
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
CN109893664B
(zh)
*
|
2017-12-11 |
2022-03-11 |
四川大学 |
一种阳离子脂质纳米颗粒/dna复合物及其制备方法
|
|
TW201936201A
(zh)
|
2017-12-14 |
2019-09-16 |
美商堅固生物科技公司 |
基因之非病毒生產及遞送
|
|
MA51306A
(fr)
|
2017-12-20 |
2020-10-28 |
Translate Bio Inc |
Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
|
|
US20230193242A1
(en)
|
2017-12-22 |
2023-06-22 |
The Broad Institute, Inc. |
Cas12b systems, methods, and compositions for targeted dna base editing
|
|
US20190298857A1
(en)
|
2018-01-09 |
2019-10-03 |
Trucode Gene Repair, Inc. |
Polymer-based nanoparticles, related formulations methods, and apparatus
|
|
US12509492B2
(en)
|
2018-01-19 |
2025-12-30 |
Duke University |
Genome engineering with CRISPR-Cas systems in eukaryotes
|
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
|
JP7550648B2
(ja)
|
2018-03-19 |
2024-09-13 |
クリスパー セラピューティクス アーゲー |
新規rnaプログラム可能エンドヌクレアーゼ系およびその使用
|
|
EP3773505B1
(de)
|
2018-03-30 |
2026-04-29 |
Insmed Incorporated |
Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
|
|
US20210123016A1
(en)
|
2018-05-02 |
2021-04-29 |
Novartis Ag |
Regulators of human pluripotent stem cells and uses thereof
|
|
EP3787602A4
(de)
|
2018-05-02 |
2022-03-23 |
Insmed Incorporated |
Verfahren zur herstellung von liposomalen arzneimittelformulierungen
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
IL324506A
(en)
|
2018-06-18 |
2026-01-01 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus vector for delivery of muscle-specific microdystrophin for the treatment of muscular dystrophy
|
|
EP3830256A2
(de)
|
2018-07-31 |
2021-06-09 |
The Broad Institute, Inc. |
Neuartige crispr-enzyme und systeme
|
|
CA3106035A1
(en)
|
2018-08-07 |
2020-02-13 |
The Broad Institute, Inc. |
Cas12b enzymes and systems
|
|
JP7436990B2
(ja)
*
|
2018-08-10 |
2024-02-22 |
国立大学法人京都大学 |
カチオン性脂質を用いた心筋細胞へのトランスフェクション方法
|
|
WO2020032184A1
(ja)
*
|
2018-08-10 |
2020-02-13 |
武田薬品工業株式会社 |
カチオン性脂質
|
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
|
US11174500B2
(en)
|
2018-08-24 |
2021-11-16 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
|
EP3853202A1
(de)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Verbindungen und zusammensetzungen zur intrazellulären verabreichung von therapeutischen wirkstoffen
|
|
CN112996854B
(zh)
|
2018-09-19 |
2024-08-30 |
摩登纳特斯有限公司 |
高纯度peg脂质和其用途
|
|
US12151029B2
(en)
|
2018-09-19 |
2024-11-26 |
Modernatx, Inc. |
PEG lipids and uses thereof
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
EP3852911B1
(de)
|
2018-09-21 |
2025-01-22 |
Acuitas Therapeutics, Inc. |
Systeme und verfahren zur herstellung von lipidnanopartikeln und liposomen
|
|
US20210322575A1
(en)
|
2018-09-28 |
2021-10-21 |
Nutcracker Therapeutics, Inc. |
Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
|
|
ES2951836T3
(es)
|
2018-10-01 |
2023-10-25 |
Alnylam Pharmaceuticals Inc |
Lípidos biodegradables para el suministro de agentes activos
|
|
DK3864163T3
(da)
|
2018-10-09 |
2024-05-06 |
Univ British Columbia |
Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
US12357705B2
(en)
|
2018-11-09 |
2025-07-15 |
Arbutus Biopharma Corporation |
Negatively charged peg-lipid conjugates
|
|
CN113286882A
(zh)
|
2018-11-09 |
2021-08-20 |
阿布特斯生物制药公司 |
脂质纳米颗粒制剂
|
|
AU2019376006B2
(en)
|
2018-11-09 |
2026-07-02 |
Arbutus Biopharma Corporation |
Cationic lipids containing silicon
|
|
AU2019384557B2
(en)
|
2018-11-21 |
2025-07-17 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
|
|
CA3121191A1
(en)
|
2018-11-28 |
2020-06-04 |
Crispr Therapeutics Ag |
Optimized mrna encoding cas9 for use in lnps
|
|
CA3121528A1
(en)
|
2018-12-12 |
2020-06-18 |
Flagship Pioneering Innovations V, Inc. |
Anellosomes and methods of use
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
KR20210113273A
(ko)
|
2019-01-09 |
2021-09-15 |
애로우헤드 파마슈티컬스 인코포레이티드 |
HIF-2 알파 (EPAS1)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법
|
|
PL3908568T3
(pl)
|
2019-01-11 |
2024-12-02 |
Acuitas Therapeutics, Inc. |
Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
|
|
CN113939282A
(zh)
|
2019-01-31 |
2022-01-14 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
|
US12534714B2
(en)
|
2019-03-18 |
2026-01-27 |
The Broad Institute, Inc. |
Type VII CRISPR proteins and systems
|
|
EP3711749A1
(de)
|
2019-03-19 |
2020-09-23 |
Polymun Scientific Immunbiologische Forschung GmbH |
Verfahren zur herstellung von lipidnanopartikeln
|
|
EP3942050A4
(de)
*
|
2019-03-19 |
2023-02-22 |
Arcturus Therapeutics, Inc. |
Verfahren zur herstellung von lipidumhüllten rna-nanopartikeln
|
|
EP3947646A1
(de)
|
2019-04-05 |
2022-02-09 |
Precision BioSciences, Inc. |
Verfahren zur herstellung von populationen genetisch modifizierter immunzellen
|
|
WO2020210805A1
(en)
|
2019-04-11 |
2020-10-15 |
The Johns Hopkins University |
Nanoparticles for drug delivery to brain
|
|
TWI887234B
(zh)
|
2019-04-14 |
2025-06-21 |
美國公爵大學 |
治療杜興氏(duchenne)肌肉失養症之大型突變熱點之aav載體介導之刪除
|
|
CN114026228A
(zh)
|
2019-05-07 |
2022-02-08 |
精密生物科学公司 |
用于识别序列的工程化大范围核酸酶的优化
|
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
WO2020255008A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
|
|
US20220273715A1
(en)
|
2019-07-25 |
2022-09-01 |
Precision Biosciences, Inc. |
Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
|
|
GB2600859B
(en)
|
2019-08-14 |
2024-04-03 |
Acuitas Therapeutics Inc |
Improved lipid nanoparticles for delivery of nucleic acids
|
|
CN114929205B
(zh)
|
2019-09-06 |
2024-09-03 |
世代生物公司 |
包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
|
|
AU2020351220A1
(en)
|
2019-09-19 |
2022-04-07 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4031524A1
(de)
|
2019-09-19 |
2022-07-27 |
ModernaTX, Inc. |
Lipidverbindungen mit verzweigtem ende und zusammensetzungen zur intrazellulären abgabe therapeutischer mittel
|
|
CA3155003A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
|
AU2020385378A1
(en)
|
2019-11-22 |
2022-04-07 |
Generation Bio Co. |
Ionizable lipids and nanoparticle compositions thereof
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
CA3170547A1
(en)
|
2020-02-11 |
2021-08-19 |
Genevant Sciences Gmbh |
Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
JP7837276B2
(ja)
|
2020-03-04 |
2026-03-30 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
免疫療法に対する腫瘍細胞の感作のための方法及び組成物
|
|
JP7709981B2
(ja)
|
2020-03-17 |
2025-07-17 |
ジェネヴァント サイエンシズ ゲーエムベーハー |
肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
|
|
US12534435B2
(en)
|
2020-03-27 |
2026-01-27 |
Generation Bio Co. |
Lipids and nanoparticle compositions thereof
|
|
AU2021250814A1
(en)
|
2020-03-30 |
2022-10-13 |
BioNTech SE |
RNA compositions targeting Claudin-18.2
|
|
WO2021204179A1
(en)
|
2020-04-09 |
2021-10-14 |
Suzhou Abogen Biosciences Co., Ltd. |
Nucleic acid vaccines for coronavirus
|
|
KR20230005244A
(ko)
|
2020-04-20 |
2023-01-09 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
생물학적 활성 건조 분말 조성물 및 이의 제조 및 사용 방법
|
|
CN118490818A
(zh)
|
2020-04-22 |
2024-08-16 |
生物技术欧洲股份公司 |
冠状病毒疫苗
|
|
WO2021231259A1
(en)
|
2020-05-11 |
2021-11-18 |
Precision Biosciences, Inc. |
Self-limiting viral vectors encoding nucleases
|
|
EP4150068A1
(de)
|
2020-05-12 |
2023-03-22 |
Precision BioSciences, Inc. |
Behandlung von retinitis pigmentosa mit verbesserten manipulierten meganukleasen
|
|
CA3178965A1
(en)
|
2020-05-15 |
2021-11-18 |
Christian COBAUGH |
Messenger rna encoding cas9 for use in genome-editing systems
|
|
EP3915544A1
(de)
*
|
2020-05-25 |
2021-12-01 |
Leon-Nanodrugs GmbH |
Verfahren zur herstellung einer liposomendispersion
|
|
EP4164668A1
(de)
|
2020-06-15 |
2023-04-19 |
Research Institute at Nationwide Children's Hospital |
Adeno-assoziierte virusvektorverabreichung für muskeldystrophien
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
KR20230051172A
(ko)
|
2020-07-16 |
2023-04-17 |
아퀴타스 테라퓨틱스 인크. |
지질 나노 입자에 사용하기 위한 양이온성 지질
|
|
US20230302154A1
(en)
|
2020-08-19 |
2023-09-28 |
The Board Of Regents Of The University Of Texas System |
Nanodrugs for targeted drug delivery and use thereof
|
|
CN112206726A
(zh)
*
|
2020-09-04 |
2021-01-12 |
仲恺农业工程学院 |
海藻酸钠/乳脂粉昆虫病毒微胶囊及其制备方法
|
|
IL301253A
(en)
|
2020-09-13 |
2023-05-01 |
Arcturus Therapeutics Inc |
As a mass of large RNA lipid nanoparticles
|
|
WO2022060871A1
(en)
|
2020-09-15 |
2022-03-24 |
Verve Therapeutics, Inc. |
Lipid formulations for gene editing
|
|
CZ310613B6
(cs)
|
2020-09-23 |
2026-01-28 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
US12678406B2
(en)
|
2020-10-12 |
2026-07-14 |
Translate Bio Inc. |
Process of preparing ice-based lipid nanoparticles
|
|
MX2023004371A
(es)
|
2020-10-14 |
2023-07-26 |
George Mason Res Foundation Inc |
Lípidos ionizables, y métodos de fabricación y uso de los mismos.
|
|
WO2022099003A1
(en)
|
2020-11-06 |
2022-05-12 |
Sanofi |
Lipid nanoparticles for delivering mrna vaccines
|
|
CN117098541A
(zh)
|
2020-11-25 |
2023-11-21 |
阿卡格拉医药公司 |
用于递送核酸的脂质纳米粒及相关使用方法
|
|
AU2021403156A1
(en)
|
2020-12-18 |
2023-07-13 |
Genevant Sciences Gmbh |
Peg lipids and lipid nanoparticles
|
|
MX2023007574A
(es)
|
2020-12-22 |
2023-09-29 |
CureVac SE |
"vacuna de arn contra variantes de sars-cov-2.
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
MX2023009757A
(es)
|
2021-02-26 |
2023-09-04 |
Ethris Gmbh |
Formulaciones para la formacion de aerosoles y aerosoles para la administracion de acido nucleico.
|
|
EP4059491A1
(de)
*
|
2021-03-17 |
2022-09-21 |
Evonik Operations GmbH |
Vorrichtung und verfahren zur herstellung von nanocarriern und/oder nanoformulierungen
|
|
EP4319803B1
(de)
|
2021-04-08 |
2025-11-26 |
Vaxthera SAS |
Mosaikproteinhaltige coronavirus-impstoff
|
|
US20240200046A1
(en)
|
2021-04-22 |
2024-06-20 |
Precision Biosciences, Inc. |
Engineered meganucleases that target human mitochondrial genomes
|
|
IL307834A
(en)
|
2021-04-22 |
2023-12-01 |
Prec Biosciences Inc |
Transgenic meganonucleases targeting human mitochondrial genomes
|
|
CA3173953A1
(en)
|
2021-06-11 |
2023-12-10 |
Tyson D. BOWEN |
Rna polymerase iii promoters and methods of use
|
|
CN117642380A
(zh)
|
2021-06-14 |
2024-03-01 |
世代生物公司 |
阳离子脂质及其组合物
|
|
KR20240051112A
(ko)
|
2021-07-01 |
2024-04-19 |
인답타 세라뷰틱스 인코포레이티드 |
조작된 자연 살해(nk) 세포 및 관련 방법
|
|
CZ310443B6
(cs)
|
2021-07-19 |
2025-06-25 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
US20240254483A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
WO2023044343A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
TW202327646A
(zh)
|
2021-10-15 |
2023-07-16 |
美商輝瑞大藥廠 |
Rna分子
|
|
EP4426828A1
(de)
|
2021-11-01 |
2024-09-11 |
Tome Biosciences, Inc. |
Einzelkonstruktplattform zur gleichzeitigen abgabe von geneditierungsmaschinen und nukleinsäurefracht
|
|
US20250043269A1
(en)
|
2021-11-03 |
2025-02-06 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad |
Precise Genome Editing Using Retrons
|
|
US20250049948A1
(en)
|
2021-11-16 |
2025-02-13 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
EP4436549A1
(de)
|
2021-11-22 |
2024-10-02 |
Sail Biomedicines, Inc. |
Neue ionisierbare lipide und lipidnanopartikel und verfahren zur verwendung davon
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
CA3242399A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Fluorinated cationic lipids for use in lipid nanoparticles
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
EP4700017A2
(de)
|
2021-12-16 |
2026-02-25 |
Acuitas Therapeutics Inc. |
Fluorierte kationische lipide zur verwendung in lipidnanopartikeln
|
|
EP4448002A1
(de)
|
2021-12-17 |
2024-10-23 |
Pfizer Inc. |
Polynukleotidzusammensetzungen und verwendungen davon
|
|
US20250057980A1
(en)
|
2021-12-22 |
2025-02-20 |
Tome Biosciences, Inc. |
Co-Delivery of a Gene Editor Construct and a Donor Template
|
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
US20250082777A1
(en)
|
2022-01-10 |
2025-03-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
JP2025508332A
(ja)
|
2022-01-27 |
2025-03-26 |
ビオンテック エスエー |
単純ヘルペスウイルス抗原の送達のための薬学的組成物及び関連方法
|
|
WO2023144792A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
|
|
KR20240146674A
(ko)
|
2022-01-31 |
2024-10-08 |
제네반트 사이언시즈 게엠베하 |
지질 나노입자를 위한 이온화 가능한 양이온성 지질
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023178182A1
(en)
|
2022-03-16 |
2023-09-21 |
10X Genomics, Inc. |
Compositions and methods for detection and treatment of coronavirus infection
|
|
CA3245624A1
(en)
|
2022-03-25 |
2023-09-28 |
Sail Biomedicines, Inc. |
NEW IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND THEIR METHODS OF USE
|
|
US12011507B2
(en)
|
2022-04-01 |
2024-06-18 |
Nanovation Therapeutics Inc. |
MRNA delivery composition
|
|
AU2023250649A1
(en)
|
2022-04-04 |
2024-11-14 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
|
CA3255619A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
EP4507719A1
(de)
|
2022-04-13 |
2025-02-19 |
Universitat Autònoma de Barcelona |
Behandlung neuromuskulärer erkrankungen mittels gentherapie mit expression von klotho-protein
|
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
|
EP4519438A1
(de)
|
2022-05-05 |
2025-03-12 |
The Board of Trustees of the Leland Stanford Junior University |
Interferierende rna-therapie für pln-r14del-kardiomyopathie
|
|
AU2023268051A1
(en)
|
2022-05-13 |
2025-01-02 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
|
WO2023230587A2
(en)
|
2022-05-25 |
2023-11-30 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
WO2023230295A1
(en)
|
2022-05-25 |
2023-11-30 |
BioNTech SE |
Rna compositions for delivery of monkeypox antigens and related methods
|
|
US20250375534A1
(en)
|
2022-05-30 |
2025-12-11 |
BioNTech SE |
Complexes for delivery of nucleic acids
|
|
GB202208022D0
(en)
|
2022-05-31 |
2022-07-13 |
Sisaf Ltd |
Therapeutic compounds and compositions
|
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
CA3260237A1
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression
|
|
US11878055B1
(en)
|
2022-06-26 |
2024-01-23 |
BioNTech SE |
Coronavirus vaccine
|
|
US20250375524A1
(en)
|
2022-06-30 |
2025-12-11 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
|
WO2024006863A1
(en)
|
2022-06-30 |
2024-01-04 |
Precision NanoSystems ULC |
Lipid nanoparticle formulations for vaccines
|
|
EP4554967A2
(de)
|
2022-07-12 |
2025-05-21 |
Tune Therapeutics, Inc. |
Zusammensetzungen, systeme und verfahren zur gezielten transkriptionsaktivierung
|
|
GB202210794D0
(en)
|
2022-07-22 |
2022-09-07 |
Sisaf Ltd |
Lipid formulations
|
|
AU2023323547A1
(en)
|
2022-08-12 |
2025-03-20 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
JP2025527583A
(ja)
|
2022-08-18 |
2025-08-22 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質ナノ粒子の組成物
|
|
WO2024040254A2
(en)
|
2022-08-19 |
2024-02-22 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
|
EP4577243A1
(de)
|
2022-08-26 |
2025-07-02 |
Ethris GmbH |
Stabile lipid- oder lipidoidnanopartikelsuspensionen
|
|
EP4327829A1
(de)
|
2022-08-26 |
2024-02-28 |
Ethris GmbH |
Stabilisierung von lipid- oder lipidoidnanopartikelsuspensionen
|
|
EP4581012A2
(de)
|
2022-08-31 |
2025-07-09 |
Sail Biomedicines, Inc. |
Neue ionisierbare lipide und lipidnanopartikel und verfahren zur verwendung davon
|
|
WO2024054843A2
(en)
|
2022-09-07 |
2024-03-14 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US12491482B2
(en)
|
2022-09-08 |
2025-12-09 |
Evonik Operations Gmbh |
Nanocarrier manufacturing
|
|
WO2024057237A1
(en)
|
2022-09-16 |
2024-03-21 |
Pfizer Inc. |
Lipid nanoparticles
|
|
JP2025531268A
(ja)
|
2022-09-19 |
2025-09-19 |
チューン セラピューティクス インコーポレイテッド |
T細胞機能を調節するための組成物、システム、および方法
|
|
US20260151470A1
(en)
|
2022-09-23 |
2026-06-04 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
|
IL319414A
(en)
|
2022-09-23 |
2025-05-01 |
BioNTech SE |
Compositions for delivering antigens at the liver level and related methods
|
|
KR20250110209A
(ko)
|
2022-09-23 |
2025-07-18 |
엔크로마 바이오, 인크. |
Hbv 유전자 발현의 에피제네틱 조절을 위한 조성물 및 방법
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
KR20250075643A
(ko)
|
2022-09-27 |
2025-05-28 |
레졸루션 쎄라퓨틱스 리미티드 |
치료용 대식세포
|
|
US20240108545A1
(en)
|
2022-10-03 |
2024-04-04 |
West Pharmaceutical Services, Inc. |
Methods and adapters for mixing pharmaceutical complexes
|
|
CN120129702A
(zh)
|
2022-10-06 |
2025-06-10 |
生物技术公司 |
靶向密蛋白-18.2的rna组合物
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
CN120153078A
(zh)
|
2022-10-27 |
2025-06-13 |
辉瑞大药厂 |
编码rsv-f的rna分子及含所述rna分子的疫苗
|
|
WO2024089634A1
(en)
|
2022-10-27 |
2024-05-02 |
Pfizer Inc. |
Immunogenic compositions against influenza and rsv
|
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
|
IL320338A
(en)
|
2022-11-04 |
2025-06-01 |
Pfizer |
Fatty compounds and their uses
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
AU2023406321A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
EP4626402A1
(de)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipidnanopartikel mit nukleinsäuren und lipidverankerten polymeren
|
|
US20260207525A1
(en)
|
2022-12-01 |
2026-07-23 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
JP2025541726A
(ja)
|
2022-12-01 |
2025-12-23 |
ジェネレーション バイオ カンパニー |
細胞標的化のためのステルス脂質ナノ粒子組成物
|
|
JP2026500218A
(ja)
|
2022-12-11 |
2026-01-06 |
ファイザー・インク |
インフルエンザおよびrsvに対する免疫原性組成物
|
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|
|
CN121127490A
(zh)
|
2022-12-28 |
2025-12-12 |
生物技术欧洲股份公司 |
靶向hiv的rna组合物
|
|
EP4649087A2
(de)
|
2023-01-11 |
2025-11-19 |
Engage Biologics Inc. |
Nichtvirale expressionssysteme und verfahren zu ihrer verwendung
|
|
EP4651890A1
(de)
|
2023-01-16 |
2025-11-26 |
Pfizer Inc. |
Immunogene zusammensetzungen und verfahren zur auslösung einer immunreaktion gegen varicella-zoster-virus
|
|
CN120548194A
(zh)
|
2023-01-18 |
2025-08-26 |
辉瑞公司 |
针对呼吸道疾病的疫苗
|
|
WO2024161249A1
(en)
|
2023-01-31 |
2024-08-08 |
Pfizer Inc. |
Lipid compounds and uses thereof
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024194756A1
(en)
|
2023-03-17 |
2024-09-26 |
Pfizer Inc. |
Modulating the innate immunity of rna
|
|
JP2026520816A
(ja)
|
2023-04-19 |
2026-06-25 |
グラダリス,インコーポレイティド |
シアル酸産生を調節して遺伝性封入体ミオパチー(hibm)を治療するための組成物及び方法
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
AU2024266138A1
(en)
|
2023-05-03 |
2025-11-13 |
Manifold Biotechnologies, Inc. |
Methods and compositions for high-throughput protein delivery, screening, and detection
|
|
CN121038807A
(zh)
|
2023-05-03 |
2025-11-28 |
生物技术欧洲股份公司 |
优化的csp变体及相关方法
|
|
CN121443580A
(zh)
|
2023-05-05 |
2026-01-30 |
爱康泰生治疗公司 |
用于脂质纳米颗粒制剂的脂质
|
|
WO2024234006A1
(en)
|
2023-05-11 |
2024-11-14 |
Tome Biosciences, Inc. |
Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
|
|
JP2026523341A
(ja)
|
2023-05-15 |
2026-07-14 |
エヌクロマ・バイオ,インコーポレーテッド |
Hbv遺伝子発現のエピジェネティック調節のための組成物および方法
|
|
WO2024240962A1
(en)
|
2023-05-25 |
2024-11-28 |
Ethris Gmbh |
Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof
|
|
EP4719352A1
(de)
|
2023-05-31 |
2026-04-08 |
Capstan Therapeutics, Inc. |
Lipidnanopartikelformulierungen und zusammensetzungen
|
|
JP2026521505A
(ja)
|
2023-06-14 |
2026-06-30 |
ファイザー・インク |
Rnaを安定化するための方法
|
|
JP2026521725A
(ja)
|
2023-06-16 |
2026-07-01 |
アクイタス セラピューティクス インコーポレイテッド |
アミド含有脂質
|
|
CN121646576A
(zh)
|
2023-06-16 |
2026-03-10 |
爱康泰生治疗公司 |
用于脂质纳米颗粒的脂质
|
|
US20250025427A1
(en)
|
2023-06-16 |
2025-01-23 |
Acuitas Therapeutics, Inc. |
Mixed amide ester containing lipids for use in lipid nanoparticles
|
|
KR20260030139A
(ko)
|
2023-06-28 |
2026-03-05 |
글로벌 라이프 사이언시즈 솔루션즈 캐나다 유엘씨 |
세포 요법을 위한 지질 나노입자 제형 및 관련 방법
|
|
EP4736848A1
(de)
|
2023-06-28 |
2026-05-06 |
Shanghai Regenelead Therapies Co., Ltd. |
Pharmazeutische zusammensetzung mit kationischem lipid und verwendung davon
|
|
EP4746913A1
(de)
|
2023-07-19 |
2026-05-27 |
Pfizer Inc. |
Lipidnanopartikel mit polymerkonjugierten lipiden und verwendungen davon
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
EP4746902A2
(de)
|
2023-07-21 |
2026-05-27 |
BioNTech SE |
Zusammensetzungen zur abgabe von plasmodium-antigenen und zugehörige verfahren
|
|
EP4750488A1
(de)
|
2023-07-24 |
2026-06-03 |
BioNTech SE |
Zusammensetzungen zur abgabe von plasmodium-antigenen und zugehörige verfahren
|
|
EP4750890A2
(de)
|
2023-07-27 |
2026-06-03 |
Life Edit Therapeutics, Inc. |
Rna-geführte nukleasen und aktive fragmente und varianten davon und verfahren zur verwendung
|
|
EP4754248A1
(de)
|
2023-07-31 |
2026-06-10 |
Tune Therapeutics, Inc. |
Zusammensetzungen und verfahren zur multiplex-aktivierung und -repression der t-zell-genexpression
|
|
WO2025027492A1
(en)
|
2023-07-31 |
2025-02-06 |
Pfizer Inc. |
Coronavirus antigen variants
|
|
CN121909284A
(zh)
|
2023-07-31 |
2026-04-21 |
图恩疗法股份有限公司 |
用于调节il-2基因表达的组合物和方法
|
|
TW202519509A
(zh)
|
2023-08-01 |
2025-05-16 |
德商拜恩技術股份公司 |
可離子化硫脂質及其用途
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
EP4754130A2
(de)
|
2023-08-03 |
2026-06-10 |
BioNTech SE |
Gegen hiv gerichtete rna-zusammensetzungen
|
|
AU2024316307A1
(en)
|
2023-08-03 |
2026-02-26 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
CN121866336A
(zh)
|
2023-08-03 |
2026-04-14 |
百欧恩泰欧洲股份公司 |
靶向hiv的rna组合物
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
CN121729225A
(zh)
|
2023-08-25 |
2026-03-24 |
埃泽瑞斯公司 |
具有增强药物应用的特定表面活性剂性质的稳定脂质和类脂质纳米颗粒制剂
|
|
WO2025050069A1
(en)
|
2023-09-01 |
2025-03-06 |
Tome Biosciences, Inc. |
Programmable gene insertion using engineered integration enzymes
|
|
WO2025052278A1
(en)
|
2023-09-05 |
2025-03-13 |
Genevant Sciences Gmbh |
Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025051994A1
(en)
|
2023-09-07 |
2025-03-13 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
CN121844046A
(zh)
|
2023-09-11 |
2026-04-10 |
C·米库尔卡 |
用于递送肠促胰岛素剂的rna组合物
|
|
WO2025057115A2
(en)
|
2023-09-15 |
2025-03-20 |
Pfizer Inc. |
Methods and compositions for continuous production of nucleic acids
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072383A1
(en)
|
2023-09-25 |
2025-04-03 |
The Broad Institute, Inc. |
Viral open reading frames, uses thereof, and methods of detecting the same
|
|
CN122270550A
(zh)
|
2023-09-27 |
2026-06-23 |
分解治疗有限公司 |
治疗性巨噬细胞
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
CN122422501A
(zh)
|
2023-10-18 |
2026-07-17 |
生命编辑治疗股份有限公司 |
Rna引导的核酸酶及其活性片段和变体以及使用方法
|
|
WO2025088570A1
(en)
|
2023-10-26 |
2025-05-01 |
Crispr Therapeutics Ag |
Ionizable lipids and ionizable lipid nanoparticles
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025106754A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Coronavirus vaccine
|
|
US20250161227A1
(en)
|
2023-11-17 |
2025-05-22 |
Acuitas Therapeutics, Inc. |
Pegylated lipids
|
|
WO2025114520A1
(en)
|
2023-12-01 |
2025-06-05 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
WO2025128696A1
(en)
|
2023-12-12 |
2025-06-19 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025132122A1
(en)
|
2023-12-13 |
2025-06-26 |
Berlin Institute Of Health |
Methods of delivering therapeutics using lipid nanoparticles
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025126019A1
(en)
|
2023-12-13 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025126071A1
(en)
|
2023-12-14 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025126118A1
(en)
|
2023-12-15 |
2025-06-19 |
Pfizer Inc. |
Lipid compounds and uses thereof
|
|
WO2025126113A1
(en)
|
2023-12-15 |
2025-06-19 |
Pfizer Inc. |
Lipid compounds and uses thereof
|
|
IL328626A
(en)
|
2023-12-15 |
2026-07-01 |
Capstan Therapeutics Inc |
Humanized anti-CD8 antibodies and their uses
|
|
WO2025129158A1
(en)
|
2023-12-15 |
2025-06-19 |
The Broad Institute, Inc. |
Engineered arc delivery vesicles and uses thereof
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025134062A2
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|
|
WO2025134046A1
(en)
|
2023-12-22 |
2025-06-26 |
Pfizer Inc. |
Methods and vaccine compositions for lyme disease
|
|
AU2024409925A1
(en)
|
2023-12-26 |
2026-08-06 |
Emmune, Inc. |
Systems for nucleic acid transfer
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025163460A2
(en)
|
2024-01-30 |
2025-08-07 |
Pfizer Inc. |
Vaccines against respiratory diseases
|
|
AU2025217182A1
(en)
|
2024-02-02 |
2026-08-06 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
WO2025174908A1
(en)
|
2024-02-12 |
2025-08-21 |
Life Edit Therapeutics, Inc. |
Novel rna-guided nucleases and proteins for polymerase editing
|
|
WO2025174858A1
(en)
|
2024-02-15 |
2025-08-21 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
TW202543583A
(zh)
|
2024-03-01 |
2025-11-16 |
加拿大商阿奎特斯醫療公司 |
用於將治療劑包覆於脂質奈米顆粒中之材料及方法
|
|
WO2025186725A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Improved lnp formulations and uses thereof
|
|
WO2025186719A1
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
TW202602467A
(zh)
|
2024-03-11 |
2026-01-16 |
美商輝瑞股份有限公司 |
包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
|
|
WO2025202287A1
(en)
|
2024-03-26 |
2025-10-02 |
Resolution Therapeutics Limited |
Method of producing macrophages
|
|
US20260061042A1
(en)
|
2024-03-26 |
2026-03-05 |
Pfizer Inc. |
Polynucleotide compositions and uses thereof
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
WO2025210521A1
(en)
|
2024-04-04 |
2025-10-09 |
Genevant Sciences Gmbh |
Lipid nanoparticles for stimulating t cells
|
|
WO2025210520A1
(en)
|
2024-04-04 |
2025-10-09 |
Genevant Sciences Gmbh |
Lipid nanoparticles for inducing an immunological response
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025217264A1
(en)
|
2024-04-10 |
2025-10-16 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025219528A1
(en)
|
2024-04-17 |
2025-10-23 |
Global Life Sciences Solutions Canada Ulc |
Non-destructive plasmid delivery to immune cells
|
|
WO2025219491A1
(en)
|
2024-04-17 |
2025-10-23 |
Global Life Sciences Solutions Canada Ulc |
Method and composition for hdr template dna delivery
|
|
WO2025219199A1
(en)
|
2024-04-19 |
2025-10-23 |
Evonik Operations Gmbh |
Process for producing nanocarriers and/or nanoformulations
|
|
WO2025224107A1
(en)
|
2024-04-22 |
2025-10-30 |
Basecamp Research Ltd |
Method and compositions for detecting off-target editing
|
|
WO2025224182A2
(en)
|
2024-04-23 |
2025-10-30 |
Basecamp Research Ltd |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
TW202604548A
(zh)
|
2024-05-01 |
2026-02-01 |
加拿大商阿奎特斯醫療公司 |
使用脂質奈米顆粒進行肌內遞輸之方法
|
|
WO2025233894A1
(en)
|
2024-05-09 |
2025-11-13 |
University Of Miami |
Engineered meganucleases that target human mitochondrial genomes
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|
|
WO2025240833A1
(en)
|
2024-05-17 |
2025-11-20 |
Acuitas Therapeutics, Inc. |
Galnac lipid compounds for use in lipid nanoparticles
|
|
WO2025250808A1
(en)
|
2024-05-29 |
2025-12-04 |
The Brigham And Women’S Hospital, Inc. |
Anti-crispr delivery compositions and methods
|
|
WO2025260068A1
(en)
|
2024-06-14 |
2025-12-18 |
Tune Therapeutics, Inc. |
Lipid nanoparticle formulation for delivery of nucleic acids to cells
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
TW202617985A
(zh)
|
2024-06-25 |
2026-05-01 |
美商生命編輯治療學公司 |
新穎反轉錄酶及其用途
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026015647A1
(en)
|
2024-07-09 |
2026-01-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
|
|
WO2026015882A1
(en)
|
2024-07-12 |
2026-01-15 |
BioNTech SE |
Hsv antigen fragments and related methods
|
|
WO2026018181A1
(en)
|
2024-07-17 |
2026-01-22 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
WO2026018213A1
(en)
|
2024-07-18 |
2026-01-22 |
Vaxthera Sas |
A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026022677A1
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Permanently charged cationic lipids
|
|
WO2026022656A2
(en)
|
2024-07-22 |
2026-01-29 |
Genevant Sciences Gmbh |
Lipid particle formulations with permanently charged cationic lipids
|
|
WO2026047603A1
(en)
|
2024-08-28 |
2026-03-05 |
BioNTech SE |
Sars-cov-2 immunogenic compositions
|
|
WO2026055342A1
(en)
|
2024-09-04 |
2026-03-12 |
Arsenal Biosciences, Inc. |
Synthetic pathway activators
|
|
WO2026057626A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having multiple enzymatically active domains
|
|
WO2026057625A1
(en)
|
2024-09-11 |
2026-03-19 |
BioNTech SE |
Peptidoglycan hydrolases having a chap domain with engineered active site
|
|
WO2026064512A1
(en)
|
2024-09-18 |
2026-03-26 |
Generation Bio Co. |
Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2026064753A1
(en)
|
2024-09-23 |
2026-03-26 |
Tune Therapeutics, Inc. |
Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
|
|
WO2026072773A1
(en)
|
2024-09-27 |
2026-04-02 |
Pfizer Inc. |
Compositions and methods for reduction of double-stranded rna
|
|
WO2026068864A1
(en)
|
2024-09-30 |
2026-04-02 |
BioNTech SE |
Engineered ch1 and cl domains for the prevention of chain mispairing
|
|
WO2026078579A1
(en)
|
2024-10-08 |
2026-04-16 |
Precision Biosciences, Inc. |
Methods and compositions for treating hepatitis b virus-related conditions
|
|
WO2026078565A1
(en)
|
2024-10-10 |
2026-04-16 |
Crispr Therapeutics Ag |
Messenger rna encoding cas9 for use in genome-editing systems
|
|
WO2026083241A1
(en)
|
2024-10-15 |
2026-04-23 |
Genevant Sciences Gmbh |
Ionizable lipids comprising n,n-substituted hydroxylamine esters
|
|
WO2026082899A2
(en)
|
2024-10-16 |
2026-04-23 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2026088119A1
(en)
|
2024-10-24 |
2026-04-30 |
Pfizer Inc. |
Lipidated tlr7/8 modulators as adjuvants and uses thereof
|
|
WO2026096919A1
(en)
|
2024-11-01 |
2026-05-07 |
Sail Biomedicines, Inc. |
Novel dipepetide core lipids, lipid carriers, and methods of using thereof
|
|
WO2026101902A1
(en)
|
2024-11-05 |
2026-05-15 |
Acuitas Therapeutics, Inc. |
Novel hydroxy cycloalkyl containing lipid compounds and methods of their use
|
|
WO2026101900A1
(en)
|
2024-11-05 |
2026-05-15 |
Acuitas Therapeutics, Inc. |
Novel hydroxy cycloalkyl containing lipid compounds and methods of their use
|
|
WO2026102058A1
(en)
|
2024-11-06 |
2026-05-15 |
Tune Therapeutics, Inc. |
Methods for treating chronic hepatitis b infection and related formulations
|
|
WO2026102260A1
(en)
|
2024-11-08 |
2026-05-15 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)
|
|
WO2026112426A1
(en)
|
2024-11-25 |
2026-05-28 |
Gradalis, Inc. |
Composition and method for treating cancer with chromosome translocation fusion
|
|
WO2026119817A1
(en)
|
2024-12-02 |
2026-06-11 |
BioNTech SE |
Agents and methods for targeted delivery of immune effector cells
|
|
WO2026125598A1
(en)
|
2024-12-13 |
2026-06-18 |
BioNTech SE |
Measuring nucleic acid integrity
|
|
WO2026125590A1
(en)
|
2024-12-13 |
2026-06-18 |
BioNTech SE |
Measuring nucleic acid integrity
|
|
WO2026136246A1
(en)
|
2024-12-16 |
2026-06-25 |
Acuitas Therapeutics, Inc. |
Novel lipid compounds and methods of their use
|
|
WO2026136222A1
(en)
|
2024-12-16 |
2026-06-25 |
Acuitas Therapeutics, Inc. |
Cycloalkyl containing lipids for use in lipid nanoparticles
|
|
WO2026136224A1
(en)
|
2024-12-16 |
2026-06-25 |
Acuitas Therapeutics, Inc. |
Novel lipid compounds for lipid nanoparticle formulation and uses of the same
|
|
WO2026136225A1
(en)
|
2024-12-16 |
2026-06-25 |
Acuitas Therapeutics, Inc. |
Urea or carbamate containing lipids and uses of the same
|
|
US20260166136A1
(en)
|
2024-12-18 |
2026-06-18 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
WO2026148356A1
(en)
|
2025-01-06 |
2026-07-09 |
BioNTech SE |
Coronavirus and influenza immunogenic combinations
|
|
WO2026150132A1
(en)
|
2025-01-12 |
2026-07-16 |
BioNTech SE |
Combination therapy comprising an rna cancer vaccine and a multispecific binding agent targeting pd-1/pd-l1 and vegf/vegfr for cancer treatment
|
|
WO2026159577A1
(en)
|
2025-01-22 |
2026-07-30 |
Pfizer Inc. |
Lipid nanoparticles comprising polymer-conjugated lipids and uses thereof
|
|
WO2026161895A1
(en)
|
2025-01-27 |
2026-07-30 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression
|
|
WO2026162682A1
(en)
|
2025-01-29 |
2026-08-06 |
BioNTech SE |
Compositions for delivery of plasmodium rh5 antigens and related methods
|
|
WO2026162552A1
(en)
|
2025-01-31 |
2026-08-06 |
BioNTech SE |
Agents and methods for targeted delivery to cells
|